Latest Intelligence on Central Nervous System in Asia-Pacific

Published within

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

Huntington's disease: lucrative untapped market

Given the relatively small number of patients with Huntington's disease, a neurodegenerative genetic disorder, interest in this field from leading pharma players has been limited. However, with a genetic test available for this disorder, a shift in thinking towards niche conditions, and developments in the understanding of the disease, Huntington's has the potential to become a lucrative market.

Published By Datamonitor
10 Jan 2008
Expert View
Expert View

Anti-smoking vaccines: set to ignite underdeveloped prescription market

Although many smokers are keen to kick their habit, will power by itself is often not sufficient and smoking cessation aids are often needed. The prescription nicotine dependence market is set to grow strongly at a compound annual growth rate of 16% to reach $4.6 billion by 2016, driven by two promising pipeline nicotine vaccines and Pfizer's popular nicotine receptor agonist Chantix.

Published By Datamonitor
25 Jan 2008
CommentWire
CommentWire

Medivation: Dimebon ever closer to Alzheimer's market

Medivation is set to announce trial data regarding behavioral symptoms and the impact on caregivers relating to its Alzheimer's disease drug, Dimebon. Positive findings will enhance the validity of the impressive Phase II clinical trial data published in 2007. Dimebon is forecast for a 2011 launch, and is expected to account for 15% ($1.5 billion) of the $9.5 billion AD market by 2017.

Published By Datamonitor
14 Mar 2008
ResearchWire
ResearchWire

ADHD: immature adult market continues to offer greatest commercial potential

Published By Datamonitor
14 May 2008
CommentWire
CommentWire

Nabi: pharmaceutical giants should cough up for smoking vaccine

Positive interim results, assessing the antibody response and safety of a 400mcg, six-dose immunization schedule of Nabi Biopharmaceuticals' NicVAX, provide a new indication of the vaccine's potential to treat nicotine addiction and prevent smoking relapse. These results make the product a more attractive licensing proposition as Nabi gears up to initiate pivotal Phase III trials.

Published By Datamonitor
25 Jul 2008
CommentWire
CommentWire

Pfizer: shooting itself in the foot with Chantix study

New full data from a 52-week, Pfizer-sponsored study demonstrated no significant difference in six-month and one-year quit rates between a nicotine replacement therapy patch and Pfizer's Chantix. Although these results are disappointing for Pfizer, they open up the market to developmental vaccine treatments which are able to demonstrate greater safety and efficacy than available options.

Published By Datamonitor
30 Jul 2008
CommentWire
CommentWire

Eli Lilly: further Zyprexa Adhera delays benefit Johnson & Johnson

Following the FDA's complete response letter for the drug, Eli Lilly has begun preparing a proposed risk evaluation mitigation strategy for Zyprexa Adhera. After the regulator's previous non-approval letter requesting more information regarding adverse effects in clinical trials, this further delay plays into the hands of Johnson & Johnson's direct competitor product paliperidone palmitate.

Published By Datamonitor
08 Jan 2009
CommentWire
CommentWire

Lundbeck: limited last-line US positioning awaits Serdolect

The FDA-appointed Psychopharmacology Drug Advisory Committee has voted against the use of Lundbeck's Serdolect in a broad schizophrenia population due to safety concerns, recommending approval for the treatment of refractory patients only. With disappointing sales in Europe following the drug's 2005 relaunch, the return on investment for Lundbeck to enter the US with Serdolect is unclear.

Published By Datamonitor
08 Apr 2009
CommentWire
CommentWire

Boehringer Ingelheim: Mirapex once-daily development on-track but commercial potential unclear

Recently released data show that the Mirapex once-daily formulation was superior to placebo in early Parkinson's disease patients, and comparable with the thrice-daily version of the drug. With generic versions of Mirapex expected in early 2010, the development of this reformulation may be too late to prevent significant revenue loss for Boehringer Ingelheim.

Published By Datamonitor
01 May 2009
Expert View
Expert View

APA meeting 2009: clinical data support potential label expansions in GAD

In May 2009, Datamonitor attended the annual American Psychiatric Association meeting in San Francisco. At the conference, AstraZeneca and Pfizer presented data for two high-profile products for which they hope to gain label expansions into generalized anxiety disorder. However, both companies have found pursuing this expansion to be challenging.

Published By Datamonitor
29 May 2009

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

No help is available.